The number of people with susceptibility test result for rifampicin in United States
United States: The number of people with susceptibility test result for rifampicin was 94.32 in 2021. ▲ Rising
Latest (2021)
94.32
Change on year
down 0.4%
World rank
53rd
of 146 countries
All-time high
94.71
in 2020
All-time low
89.42
in 2017
Years of data
5
2017–2021
The number of people with susceptibility test result for rifampicin in United States, 2017–2021
Source: World Health Organization, Global Health Observatory.
Analysis
The most recent figure for the number of people with susceptibility test result for rifampicin in United States is 94.32, measured in 2021.
The figure is down 0.4% on the previous year and up 5.5% over five years.
United States ranks 53rd of 146 countries on this measure, in the middle of the range.
The number of people with susceptibility test result for rifampicin in United States, year by year
| Year | Value | Change |
|---|---|---|
| 2017 | 89.42 | — |
| 2018 | 89.6 | +0.2% |
| 2019 | 93.89 | +4.8% |
| 2020 | 94.71 | +0.9% |
| 2021 | 94.32 | -0.4% |
United States compared with similar countries
- United States's 94.32 is above the median for high income countries, which is 92.6, 1.0× the median. (56 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 90.97 | 89.42 | 93.89 | 3 |
| 2020s | 94.51 | 94.32 | 94.71 | 2 |
Countries ranked near United States
More health data for United States
- Un projection of annual infant deaths, annual growth rate -1.67 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate -0.1867 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,069 deaths per 1,000 people (2090)
- Number of infants who die before age 1 4,015 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2023)
- Population ages 00-04, female, annual growth rate 0.056 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0261 units per person (2025)
- Population ages 00-04, male, annual growth rate 0.1919 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is the number of people with susceptibility test result for rifampicin in United States?
- The number of people with susceptibility test result for rifampicin in United States was 94.32 in 2021, according to World Health Organization, Global Health Observatory.
- What is the highest the number of people with susceptibility test result for rifampicin recorded in United States?
- The highest recorded value was 94.71 in 2020.
- What is the lowest the number of people with susceptibility test result for rifampicin recorded in United States?
- The lowest recorded value was 89.42 in 2017.
- How does United States rank for the number of people with susceptibility test result for rifampicin?
- United States ranks 53rd out of 146 countries with data for 2021.
- Where does this United States data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 5 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).